| 영문 | insulin | 한글 | 인슐린 |
|---|---|---|---|
| 설명 | 이자 랑겔한스섬의 B세포가 합성-분비하는 호르몬 단백질, 포도당을 글리코겐으로 바꾸는 호르몬단백질로, 분자량은 5,807이다. 혈중의 당농도 상승으로 인하여 분비가 촉진된다. 근육-지방조직-간 등 표적세포의 수용체 단백질과 결합하여 정보를 세포내로 전달함으로써 혈액 중에서 당, 지질, 아미노산 대사를 조절한다. 당의 조직에 받아드리는 것을 촉진하여 혈당을 저하시킨다. 생성-분비량 저하, 조직세포의 수용체 부족은 고혈당의 원인이 된다. 또한 아미노산의 흡수와 단백질, 지방의 합성을 촉진하며 지방분해는 억제한다. 인슐린은 이자활성성분의 약품으로서 당뇨병 및 기타 질환의 치료에 사용된다. 인슐린이라는 명칭은 섬이란 뜻의 라틴어인 insula에서 연유한다. 1921년 캐나다의 의사 F.G. 밴팅과 C.H. 베스트에 의하여 처음으로 이자에서 채취되었고, 그 후 인슐린의 결정을 얻게 되었다. F. 생거에 의해서 소의 인슐린의 구조가 밝혀졌는데(1955), 이것은 단백질 중에서는 최초로 구조식이 밝혀진 것이다. 포도당으로부터 글리코겐의 생성, 포도당의 산화 및 지방으로의 전화 등을 촉진하는 작용이 있다. 따라서 인슐린의 수용액을 주사하면 혈당이 저하하므로 당뇨병의 치료에 쓰인다. 또 인슐린을 피하에 대량 주사하면 혼수에 빠지는 것을 이용하여 정신병 치료에 인슐린쇼크요법으로서 쓰인다. |
||
| 영문 | IDDM(Insulin-Dependent Diabetes Mellitus) | 한글 | 인슐린의존당뇨병 |
|---|---|---|---|
| 설명 | IDDM은 당뇨병의 치료에 반드시 인슐린이 필요한 경우를 말한다. 주로 원인이 이자에 있는 인슐린을 분비하는 세포의 파괴이며 이로 인해서 당뇨병의 치료제로 쓰이는 인슐린의 분비를 촉진하는 약물이 이 IDDM에서는 쓰일 수가 없고 오직 인슐린만이 치료제로 쓸 수가 있다. 전형적인 인슐린 의존형 당뇨병은 소아에서 흔히 발생하고 인슐린 분비세포의 파괴에 의해서 인슐린 분비능은 거의 없다. |
||
| NPH | 1) Neutral Protamine Hagedorn Insulin = Isophane Insulin Susp... |
|---|---|
| AITT | arginine insulin tolerance test; augmented insulin tolerance test |
| IRI | immunoreactive insulin; insulin resistance index |
| IRS | immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub... |
| IST | inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci... |
| AIR | Acute insulin response |
|---|---|
| AIRg | Acute insulin response to glucose |
| BHI | Biosynthetic Human Insulin |
| IGF-1 | C--insulin-like growth factor-1 |
| IGF-I | C/insulin-like growth factor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| insulin | <drug, growth factor, hormone> A polypeptide hormone (bovine insulin, 5780D) found in both vertebrates and invertebrates. Secreted by the _ cells of the pancreas in response to high blood sugar levels, it induces hypoglycaemia. Defective secretion of insulin is the cause of diabetes mellitus. Insulin is also a mitogen, has sequence homologies with other growth factors and is a frequent addition to cell culture media for demanding cell types. (18 Nov 1997) |
|---|---|
| insulin activating factor | <chemical> Activates insulin gene transcription in pancreatic beta cells. Synonym: insaf (05 Dec 1998) |
| insulin allergy | When a person's body has an allergic or bad reaction to taking insulin made from pork or beef or from bacteria, or because the insulin is not exactly the same as human insulin or because it has impurities. The allergy can be of two forms. Sometimes an area of skin becomes red and itchy around the place where the insulin is injected. This is called a local allergy. In another form, a person's whole body can have a bad reaction. This is called a systemic allergy. The person can have hives or red patches all over the body or may feel changes in the heart rate and in the rate of breathing. A doctor may treat this allergy by prescribing purified insulins or by desensitisation. See: desensitisation. (09 Oct 1997) |
| insulin antagonist | Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin. (09 Oct 1997) |
| insulin binding | When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with the outer part of the cell. The cell then can bring glucose (sugar) inside and use it for energy. With the help of insulin, the cell can do its work very well and very quickly. But sometimes the body acts against itself. In this second case, the insulin binds with antibodies. If the insulin is an injected form of insulin and not made by the body, the body sees the insulin as an outside or foreign substance. When the injected insulin binds with the antibodies, it does not work as well as when it binds directly to the cell. (09 Oct 1997) |
| insulin c-peptide | <investigation> A blood test which measures the amount of C-peptide in the blood. C-peptide is a byproduct of normal insulin production by the beta cells in the pancreas. Normal values are 0.5 to 3.0 ng/ml. Normal levels indicate that the body is still producing its own insulin. Low levels indicate that the pancreas is producing little or no insulin. Elevations can be seen in cases of insulinomas and islet of Langerhans tumours. (27 Sep 1997) |
| insulin coma treatment | Rarely used treatment of major mental illness by means of hypoglycaemic coma induced by insulin. (05 Mar 2000) |
| insulin dependent diabetes | A form of diabetes that requires the daily injection of the hormone insulin to maintain normal body chemistry. Avoidance of insulin in these patients will result in a severe metabolic derangement known as diabetic ketoacidosis. (27 Sep 1997) |
| insulin hypoglycaemia test | A test to determine the completeness of vagotomy for peptic ulcer; after the surgical procedure is performed, insulin is administered to cause hypoglycaemia; if vagotomy is complete, the acid output from the stomach following administration of insulin is less than that before insulin administration; if the reverse if true, incomplete vagotomy is likely. Synonym: Hollander test. (05 Mar 2000) |
| insulin infusion systems | Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor. (12 Dec 1998) |
| insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| insulin like growth factor | <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin. They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present). Insulin like growth factor I = somatomedin A = somatomedin C Insulin like growth factor II = MSA (Multiplication stimulating activity). Insulin like growth factor 1 is released from the liver in response to growth hormone. Acronym: IGF (18 Nov 1997) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin lipoatrophy | Dystrophic atrophy of subcutaneous tissues in diabetics at the site of frequent injections of insulin. Synonym: insulin lipoatrophy. (05 Mar 2000) |
| insulin lipodystrophy | Dystrophic atrophy of subcutaneous tissues in diabetics at the site of frequent injections of insulin. Synonym: insulin lipoatrophy. (05 Mar 2000) |
| amorphous insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
|---|---|
| anti-insulin | A factor, usually an antibody, which antagonises the action of insulin. (05 Mar 2000) |
| anti-insulin antibody | A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result. (27 Sep 1997) |
| biphasic insulin | <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin. (09 Oct 1997) |
| receptors, insulin | Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation. (12 Dec 1998) |
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| regular insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
| regular insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| globin insulin | A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours. Synonym: globin insulin. (05 Mar 2000) |
| globin zinc insulin | A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours. Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes. Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin. Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus. Synonym: NPH insulin. (05 Mar 2000) |
| crystalline insulin zinc suspension | A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours. Synonym: crystalline insulin zinc suspension. (05 Mar 2000) |
| prompt insulin zinc suspension | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
| protamine zinc insulin | Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml. (05 Mar 2000) |
| semilente insulin | Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection. Synonym: amorphous insulin zinc suspension, semilente insulin. (05 Mar 2000) |
Synonyms : Humulin, Humulin S, Iletin, Insulin A Chain, Insulin, Globin Zinc, Insulin, Regular, Insulin, Regular, Beef-Pork, Insulin, Regular, Human, Insulin, Regular, Pork, Novolin, Sodium Insulin, Type I Insulin, Type II Insulin, Velosulin, Globin Zinc Insulin
Synonyms : Antagonists, Insulin
Synonyms : Antibodies, Insulin
Synonyms : Insulin Shock, Coma, Insulin, Shock, Insulin
Synonyms : Implantable Programmable Insulin Pump, Insulin Pump, Programmable Implantable, Pump, Programmable Implantable Insulin, Artificial Endocrine Pancreas, Artificial beta Cell, Artificial beta Cells, Cell, Artificial beta, Cells, Artificial beta
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
프로타판비프주100단위 - 새창
|
녹십자 |
A10202441 | Insulin bovine | 전문의약품 | 삭제 |
|
휴마로그주 - 새창
|
Lilly |
E00510271 | Insulin lispro | 전문의약품 | 급여 | 분업예외의약품 |
|
휴마로그주Pen3ml - 새창
|
Lilly |
E00510272 | Insulin lispro | 전문의약품 | 급여 | 분업예외의약품 |
|
액트라피드비프주100단위 - 새창
|
녹십자 |
A10202421 | Insulin bovine | 전문의약품 | 삭제 |
|
프로타판비프주40단위 - 새창
|
녹십자 |
A10202291 | Insulin bovine | 전문의약품 | 삭제 |
|
노보믹스30플렉스펜주100단위/ml - 새창
|
노보노디스크 |
E08720341 | Insulin aspart | 전문의약품 | 급여 |
|
란투스주옵티셋 - 새창
|
Aventis |
E06400301 | Insulin glargine | 전문의약품 | 급여 |
|
란투스주카트리지 - 새창
|
사노피-아벤티스코리아 |
E06400231 | Insulin glargine | 전문의약품 | 삭제 |
|
란투스주바이알 - 새창
|
Aventis |
E06400221 | Insulin glargine | 전문의약품 | 급여 |
|
노보래피드주100단위/ml - 새창
|
노보노디스크 |
E08720311 | Insulin aspart | 전문의약품 | 급여 |
| insulin |
hormone secreted by the isles of Langerhans in the pancreas; regulates storage of glycogen in the liver and accelerates oxidation of sugar in cells
출처: wordnet.princeton.edu/perl/webwn
|
|---|---|
| insulin shock therapy |
insulin shock: the administration of sufficient insulin to induce convulsions and coma
출처: wordnet.princeton.edu/perl/webwn
|
| insulin shock |
hypoglycemia produced by excessive insulin in the system causing coma the administration of sufficient insulin to induce convulsions and coma
출처: wordnet.princeton.edu/perl/webwn
|
| insulin-dependent diabetes mellitus |
type I diabetes: severe diabetes mellitus with an early onset; characterized by polyuria and excessive thirst and increased appetite and weight loss and episodic ketoacidosis; diet and insulin injections are required to control the disease
출처: wordnet.princeton.edu/perl/webwn
|
| insulin lipoatrophy |
localized lipoatrophy occurring at the site of repeated insulin injections.
출처: www.mercksource.com/pp/us/cns/cns_hl_dorlands.jspz...
|
| Insulin | hormone secreted by the isles of Langerhans in the pancreas |
|---|---|
| Insulin | hypoglycemia produced by excessive insulin in the system causing coma |
| Insulin | the administration of sufficient insulin to induce convulsions and coma |
| Insulin | hypoglycemia produced by excessive insulin in the system causing coma |
| Insulin | the administration of sufficient insulin to induce convulsions and coma |
| Insulin | the administration of sufficient insulin to induce convulsions and coma |
| Insulin | severe diabetes mellitus with an early onset |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|